On February 4, 2026 Coherus Oncology, Inc. (NASDAQ: CHRS) reported a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This agreement is representative of our strategy to accelerate development of our pipeline through partnerships and differentiated combinations," said Denny Lanfear, Chairman and Chief Executive Officer at Coherus. "We continue to advance our strategic vision to build a portfolio of first-in-class and best-in-class therapies designed to deliver a step change in survival for patients with difficult-to-treat cancers."

Under the terms of the clinical supply agreement, Johnson & Johnson will provide pasritamig to Coherus, who will be the sponsor of the Phase 1b clinical trial. Johnson & Johnson and Coherus each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

(Press release, Coherus Oncology, FEB 4, 2026, View Source [SID1234662464])